Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HCP1904-2
- Development stage
- Phase 1
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**HCP1904-2** is an oral fixed-dose antihypertensive combination developed by Hanmi Pharmaceutical for essential hypertension. It was evaluated in a randomized, double-blind Phase 3 study in patients whose blood pressure was inadequately controlled with RLD2001-2 monotherapy. Public trial records establish that HCP1904-2 is a combination product, but do not publicly disclose the individual active-ingredient identities or the exact strength associated with this specific code.
- Brand names
- Closone
- Other names
- losartan potassium + chlorthalidonelosartan + chlorthalidone
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on HCP1904-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HCP1904-2.